<DOC>
	<DOC>NCT00663026</DOC>
	<brief_summary>The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.</brief_summary>
	<brief_title>Study Evaluating Bapineuzumab In Alzheimer Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis of probable Alzheimer Disease according to National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer`s Disease and Related Disorders Association (NINCDS/ADRDA) criteria MiniMental State Examination (MMSE) score 1626 Magnetic Resonance Imaging (MRI) showing other brain abnormalities Other diagnosed neurological or psychiatric disorders</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
</DOC>